Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds

Journal of Medicinal Chemistry

Volumn 55, Issue 6, 2012, Pages 2899-2903

  Hou, Zengye ^a   Nakanishi, Isao ^b   Kinoshita, Takayoshi ^c   Takei, Yoshinori ^a   Yasue, Misato ^a   Misu, Ryosuke ^a   Suzuki, Yamato ^a   Nakamura, Shinya ^b   Kure, Tatsuhide ^b   Ohno, Hiroaki ^a   Murata, Katsumi ^a   Kitaura, Kazuo ^a   Hirasawa, Akira ^a   Tsujimoto, Gozoh ^a   Oishi, Shinya ^a   Fujii, Nobutaka ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c Osaka Prefecture University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 THIADIAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CASEIN KINASE II; PROTEIN SERINE THREONINE KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; REACTION OPTIMIZATION; STRUCTURE ACTIVITY RELATION;

ADENOSINE TRIPHOSPHATE; ADENYLYL IMIDODIPHOSPHATE; ANTINEOPLASTIC AGENTS; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84858735144     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2015167     Document Type: Article

References (33)

1. Pinna, L. A. The raison d'être of constitutively active protein kinases: the lesson of CK2 Acc. Chem. Res. 2003, 36, 378-384
2. Meggio, F.; Pinna, L. A. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003, 17, 349-368 (Pubitemid 36292951)
3. Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death Biochem. J. 2003, 369, 1-15 (Pubitemid 36174119)
4. Guerra, B.; Siemer, S.; Boldyreff, B.; Issinger, O.-G. Protein kinase CK2: evidence for a protein kinase CK2β subunit fraction, devoid of the catalytic CK2α subunit, in mouse brain and testicles FEBS Lett. 1999, 462, 353-357
5. Unger, G. M.; Davis, A. T.; Slaton, J. W.; Ahmed, K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy Curr. Cancer Drug Targets. 2004, 4, 77-84 (Pubitemid 38332566)
6. Ahmad, K. A.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Protein kinase CK2: a key suppressor of apoptosis Adv. Enzyme Regul. 2008, 48, 179-187
7. Scaglioni, P. P.; Yung, T. M.; Cai, L. F.; Erdjument-Bromage, H.; Kaufman, A. J.; Singh, B.; Teruya-Feldstein, J.; Tempst, P.; Pandolfi, P. P. A CK2-dependent mechanism for degradation of the PML tumor suppressor Cell 2006, 126, 269-283 (Pubitemid 44092959)
8. Piazza, F. A.; Ruzzene, M.; Gurrieri, C.; Montini, B.; Bonanni, L.; Chioetto, G.; Di Maira, G.; Barbon, F.; Cabrelle, A.; Zambello, R.; Adami, F.; Trentin, L.; Pinna, L. A.; Semenzato, G. Multiple myeloma cell survival relies on high activity of protein kinase CK2 Blood 2006, 108, 1698-1707 (Pubitemid 44316140)
9. Mishra, S.; Pertz, V.; Zhang, B.; Kaur, P.; Shimada, H.; Groffen, J.; Kazimierczuk, Z.; Pinna, L. A.; Heisterkamp, N. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2 Leukemia 2007, 21, 178-180 (Pubitemid 44921853)
10. Sarno, S.; Pinna, L. A. Protein kinase CK2 as a druggable target Mol. Biosyst. 2008, 4, 889-894
11. Critchfield, J. W.; Coligan, J. E.; Folks, T. M.; Butera, S. T. Casein kinase II is a selective target of HIV-1 transcriptional inhibitors Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6110-6115 (Pubitemid 27270645)
12. Sarno, S.; Moro, S.; Meggio, F.; Zagotto, G.; Dal Ben, D.; Ghisellini, P.; Battistutta, R.; Zanotti, G.; Pinna, L. A. Toward the rational design of protein kinase casein kinase-2 inhibitors Pharmacol. Ther. 2002, 93, 159-168 (Pubitemid 34615557)
13. Yim, H. L.; Lee, Y. H.; Lee, C. H.; Lee, S. K. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor Planta Med. 1999, 65, 9-13 (Pubitemid 29077420)
14. Szyszka, R.; Grankowski, N.; Felczak, K.; Shugar, D. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources Biochem. Biophys. Res. Commun. 1995, 208, 418-424
15. Vangrevelinghe, E.; Zimmermann, K.; Schoepfer, J.; Portmann, R.; Fabbro, D.; Furet, P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking J. Med. Chem. 2003, 46, 2656-2662 (Pubitemid 36702534)
16. Nie, Z.; Perretta, C.; Erickson, P.; Margosiak, S.; Almassy, R.; Lu, J.; Averill, A.; Yager, K. M.; Chu, S. Structure-based design, synthesis, and study of pyrazolo[1,5- a ][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2 Bioorg. Med. Chem. Lett. 2007, 17, 4191-4195 (Pubitemid 47021399)
17. Pierre, F.; Chua, P. C.; O'Brien, S. E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M. K.; Stefan, E.; Vialettes, A.; Whitten, J. P.; Chen, T. K.; Darjania, L.; Stansfield, R.; Anderes, K.; Bliesath, J.; Drygin, D.; Ho, C.; Omori, M.; Proffitt, C.; Streiner, N.; Trent, K.; Rice, W. G.; Ryckman, D. M. Discovery and SAR of 5-(3-chlorophenylamino) benzo[ c ][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer J. Med. Chem. 2011, 54, 635-654
18. Battistutta, R.; Cozza, G.; Pierre, F.; Papinutto, E.; Lolli, G.; Sarno, S.; Brien, S. E.; Siddiqui-Jain, A.; Haddach, M.; Anderes, K.; Ryckman, D. M.; Meggio, F.; Pinna, L. A. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer Biochemistry 2011, 50, 8478-8488
19. Prudent, R.; Cochet, C. New protein kinase CK2 inhibitors: jumping out of the catalytic box Chem. Biol. 2009, 16, 112-120
20. Fuchi, N.; Iura, Y.; Kaneko, H.; Yamada, M.; Sekitani, Y. Jpn. Kokai Tokkyo Koho JP 2007145786, 2007.
21. Suzuki, Y.; Cluzeau, J.; Hara, T.; Hirasawa, A.; Tsujimoto, G.; Oishi, S.; Ohno, H.; Fujii, N. Structure-activity relationships of pyrazine-based CK2 inhibitors: synthesis and evaluation of 2,6-disubstituted pyrazines and 4,6-disubstituted pyrimidines Arch. Pharm. 2008, 341, 554-561
22. Nakaniwa, T.; Kinoshita, T.; Sekiguchi, Y.; Tada, T.; Nakanishi, I.; Kitaura, K.; Suzuki, Y.; Ohno, H.; Hirasawa, A.; Tsujimoto, G. Structure of human protein kinase CK2α2 with a potent indazole-derivative inhibitor Acta Crystallogr., Sect F: Struct. Biol. Cryst. Commun. 2009, 65, 75-79
23. Kinoshita, T.; Sekiguchi, Y.; Fukada, H.; Nakaniwa, T.; Tada, T.; Nakamura, S.; Kitaura, K.; Ohno, H.; Suzuki, Y.; Hirasawa, A.; Nakanishi, I.; Tsujimoto, G. A detailed thermodynamic profile of cyclopentyl and isopropyl derivatives binding to CK2 kinase Mol. Cell. Biochem. 2011, 356, 97-105
24. Niefind, K.; Guerra, B.; Ermakowa, I.; Issinger, O.-G. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme EMBO J. 2001, 20, 5320-5331 (Pubitemid 32959451)
25. Young, G.; Eyre, W. Oxidation of benzalthiosemicarbazone J. Chem. Soc., Perkin Trans. 1901, 79, 54-60
26. Scott, F. L.; Lambe, T. M.; Butler, R. N. Ambident oxidative ring closure of semicarbazones J. Chem. Soc., Perkin Trans. 1 1972, 1918-1923
27. Lee, J. C.; Bae, Y. H.; Chang, S. K. Efficient α-halogenation of carbonyl componds by N -bromosuccinimide and N -chlorosuccinimide Bull. Korean Chem. Soc. 2003, 24, 407-408
28. Suryakiran, N.; Srikanth Reddy, T.; Asha Latha, K.; Prabhakar, P.; Yadagiri, K.; Venkateswarlu, Y. An expeditious synthesis of 3-amino 2 H -pyrazoles promoted by methanesulphonic acid under solvent and solvent free conditions J. Mol. Catal. A: Chem. 2006, 258, 371-375 (Pubitemid 44354271)
29. Thompson, M. J.; Chen, B. Ugi reactions with ammonia offer rapid access to a wide range of 5-aminothiazole and oxazole derivatives J. Org. Chem. 2009, 74, 7084-7093
30. Kusakiewicz-Dawid, A.; Masiukiewicz, E.; Rzeszotarska, B.; Dybała, I.; Kozioł, A. E.; Broda, M. A. The synthesis, structure and properties of N -acetylated derivatives of ethyl 3-amino-1 H -pyrazole-4-carboxylate Chem. Pharm. Bull. 2007, 55, 747-752 (Pubitemid 46708600)
31. Puello, J. Q.; Obando, B. I. Structure and tautomerism of 3(5)-amino-5(3)-arylpyrazoles in the solid state and in solution: an X-Ray and NMR study Tetrahedron 1997, 53, 10783-10802 (Pubitemid 27308555)
32. Hirai, H.; Shimomura, T.; Kobayashi, M.; Eguchi, T.; Taniguchi, E.; Fukasawa, K.; Machida, T.; Oki, H.; Arai, T.; Ichikawa, K.; Hasako, S.; Haze, K.; Kodera, T.; Kawanishi, N.; Takahashi-Suziki, I.; Nakatsuru, Y.; Kotani, H.; Iwasawa, Y. Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo Cell Cycle 2010, 9, 1590-1600
33. Zeng, Q.; Bourbeau, M. P.; Wohlhieter, G. E.; Yao, G.; Monenschein, H.; Rider, J. T.; Lee, M. R.; Zhang, S.; Lofgren, J.; Freeman, D.; Li, C.; Tominey, E.; Huang, X.; Hoffman, D.; Yamane, H.; Tasker, A. S.; Dominguez, C.; Viswanadhan, V. N.; Hungate, R.; Zhang, X. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics Bioorg. Med. Chem. Lett. 2010, 20, 1652-1656